Christopher S Henney - Net Worth and Insider Trading

Christopher S Henney Net Worth

The estimated net worth of Christopher S Henney is at least $501,000 dollars as of 2024-11-13. Christopher S Henney is the Director of Cascadian Therapeutics Inc and owns about 50,000 shares of Cascadian Therapeutics Inc (CASC) stock worth over $501,000. Christopher S Henney is the Director of Prothena Corp PLC and owns about 0 shares of Prothena Corp PLC (PRTA) stock worth over $0. Christopher S Henney is also the Director of Bio-Techne Corp and owns about 0 shares of Bio-Techne Corp (TECH) stock worth over $0. Details can be seen in Christopher S Henney's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Christopher S Henney has not made any transactions after 2021-07-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Christopher S Henney

Christopher S Henney Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Christopher S Henney owns 7 companies in total, including Cyclacel Pharmaceuticals Inc (CYCC) , Prothena Corp PLC (PRTA) , and Cascadian Therapeutics Inc (CASC) among others .

Click here to see the complete history of Christopher S Henney’s form 4 insider trades.

Insider Ownership Summary of Christopher S Henney

Ticker	Comapny	Transaction Date	Type of Owner
CYCC	Cyclacel Pharmaceuticals Inc	2006-06-14	director
PRTA	Prothena Corp PLC	2021-07-14	director
CASC	Cascadian Therapeutics Inc	2018-03-09	director
		2018-01-05	director
		2012-03-23	director
		2009-03-31	director
		2004-09-17	director

Christopher S Henney Latest Holdings Summary

Christopher S Henney currently owns a total of 3 stocks. Among these stocks, Christopher S Henney owns 50,000 shares of Cascadian Therapeutics Inc (CASC) as of January 30, 2017, with a value of $501,000 and a weighting of 100%. Christopher S Henney owns 0 shares of Prothena Corp PLC (PRTA) as of July 14, 2021, with a value of $0 and a weighting of 0%. Christopher S Henney also owns 0 shares of Bio-Techne Corp (TECH) as of September 17, 2004, with a value of $0 and a weighting of 0%.

Latest Holdings of Christopher S Henney

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
CASC	Cascadian Therapeutics Inc	2017-01-30	50,000	10.02	501,000
PRTA	Prothena Corp PLC	2021-07-14	0	17.36	0
TECH	Bio-Techne Corp	2004-09-17	0	74.40	0

Holding Weightings of Christopher S Henney

Christopher S Henney Form 4 Trading Tracker

According to the SEC Form 4 filings, Christopher S Henney has made a total of 0 transactions in Cascadian Therapeutics Inc (CASC) over the past 5 years. The most-recent trade in Cascadian Therapeutics Inc is the acquisition of 25,324 shares on January 30, 2017, which cost Christopher S Henney around $104,082.

According to the SEC Form 4 filings, Christopher S Henney has made a total of 3 transactions in Prothena Corp PLC (PRTA) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Prothena Corp PLC is the sale of 11,108 shares on July 14, 2021, which brought Christopher S Henney around $616,050.

According to the SEC Form 4 filings, Christopher S Henney has made a total of 0 transactions in Bio-Techne Corp (TECH) over the past 5 years. The most-recent trade in Bio-Techne Corp is the sale of 12,000 shares on September 17, 2004, which brought Christopher S Henney around $122,280.

Insider Trading History of Christopher S Henney

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Christopher S Henney Trading Performance

GuruFocus tracks the stock performance after each of Christopher S Henney's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Christopher S Henney is 1.43%. GuruFocus also compares Christopher S Henney's trading performance to market benchmark return within the same time period. The performance of stocks bought by Christopher S Henney within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Christopher S Henney's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Christopher S Henney

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	0.72
Relative Return to S&P 500(%)	-3.71

Christopher S Henney Ownership Network

Ownership Network List of Christopher S Henney

No Data

Ownership Network Relation of Christopher S Henney

Christopher S Henney Owned Company Details

What does Cyclacel Pharmaceuticals Inc do?

Who are the key executives at Cyclacel Pharmaceuticals Inc?

Christopher S Henney is the director of Cyclacel Pharmaceuticals Inc. Other key executives at Cyclacel Pharmaceuticals Inc include director & President & C.E.O. Spiro Rombotis , director & E.V.P. & Finance & C.O.O. Paul Mcbarron , and Chief Medical Officer Mark Kirschbaum .

Cyclacel Pharmaceuticals Inc (CYCC) Insider Trades Summary

Over the past 18 months, Christopher S Henney made no insider transaction in Cyclacel Pharmaceuticals Inc (CYCC). Other recent insider transactions involving Cyclacel Pharmaceuticals Inc (CYCC) include a net purchase of 6,070 shares made by Spiro Rombotis , and a net purchase of 1,886 shares made by Paul Mcbarron .

In summary, during the past 3 months, insiders sold 0 shares of Cyclacel Pharmaceuticals Inc (CYCC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cyclacel Pharmaceuticals Inc (CYCC) were sold and 7,956 shares were bought by its insiders, resulting in a net purchase of 7,956 shares.

Cyclacel Pharmaceuticals Inc (CYCC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cyclacel Pharmaceuticals Inc Insider Transactions

No Available Data

What does Prothena Corp PLC do?

Who are the key executives at Prothena Corp PLC?

Christopher S Henney is the director of Prothena Corp PLC. Other key executives at Prothena Corp PLC include See Remarks Karin L Walker , Chief Operating Officer Brandon S. Smith , and Chief Regulatory Officer Carol D. Karp .

Prothena Corp PLC (PRTA) Insider Trades Summary

Over the past 18 months, Christopher S Henney made no insider transaction in Prothena Corp PLC (PRTA). Other recent insider transactions involving Prothena Corp PLC (PRTA) include a net sale of 45,000 shares made by Karin L Walker , a net sale of 40,000 shares made by Carol D. Karp , and a net sale of 25,000 shares made by Michael J Malecek .

In summary, during the past 3 months, insiders sold 0 shares of Prothena Corp PLC (PRTA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 321,333 shares of Prothena Corp PLC (PRTA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 321,333 shares.

Prothena Corp PLC (PRTA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Prothena Corp PLC Insider Transactions

No Available Data

What does Cascadian Therapeutics Inc do?

Who are the key executives at Cascadian Therapeutics Inc?

Christopher S Henney is the director of Cascadian Therapeutics Inc. Other key executives at Cascadian Therapeutics Inc include 10 percent owner Nea Partners 15, L.p. , 10 percent owner Jon Sakoda , and 10 percent owner Florence Anthony A. Jr. .

Cascadian Therapeutics Inc (CASC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Cascadian Therapeutics Inc (CASC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cascadian Therapeutics Inc (CASC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Cascadian Therapeutics Inc (CASC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cascadian Therapeutics Inc Insider Transactions

No Available Data

What does Anthera Pharmaceuticals Inc do?

Who are the key executives at Anthera Pharmaceuticals Inc?

Christopher S Henney is the director of Anthera Pharmaceuticals Inc. Other key executives at Anthera Pharmaceuticals Inc include Chief Medical Officer Shanahan William R Jr , Chief Regulatory Officer Klara Dickinson , and Chief Technology Officer Charles V Olson .

Anthera Pharmaceuticals Inc (ANTH) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Anthera Pharmaceuticals Inc (ANTH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Anthera Pharmaceuticals Inc (ANTH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Anthera Pharmaceuticals Inc (ANTH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Anthera Pharmaceuticals Inc Insider Transactions

No Available Data

What does Mymetics Corp do?

Who are the key executives at Mymetics Corp?

Christopher S Henney is the director of Mymetics Corp. Other key executives at Mymetics Corp include President & CEO & CFO Kempers Ronald Hugo Gerard , director & President and CEO Grant Pickering , and CEO Jacques Francois Martin .

Mymetics Corp (MYMX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Mymetics Corp (MYMX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Mymetics Corp (MYMX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Mymetics Corp (MYMX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mymetics Corp Insider Transactions

No Available Data

What does Sarepta Therapeutics Inc do?

Who are the key executives at Sarepta Therapeutics Inc?

Christopher S Henney is the director of Sarepta Therapeutics Inc. Other key executives at Sarepta Therapeutics Inc include Chief Financial Officer Ian Michael Estepan , Chief Tech Ops Officer Bilal Arif , and SVP & General Counsel Ryan Edward Brown .

Sarepta Therapeutics Inc (SRPT) Insider Trades Summary

Over the past 18 months, Christopher S Henney made no insider transaction in Sarepta Therapeutics Inc (SRPT). Other recent insider transactions involving Sarepta Therapeutics Inc (SRPT) include a net purchase of 105,570 shares made by Michael Andrew Chambers , a net sale of 40,957 shares made by Ryan Edward Brown , and a net sale of 30,000 shares made by Wigzell Hans Lennart Rudolf .

In summary, during the past 3 months, insiders sold 5,985 shares of Sarepta Therapeutics Inc (SRPT) in total and bought 37,038 shares, with a net purchase of 31,053 shares. During the past 18 months, 99,430 shares of Sarepta Therapeutics Inc (SRPT) were sold and 180,795 shares were bought by its insiders, resulting in a net purchase of 81,365 shares.

Sarepta Therapeutics Inc (SRPT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sarepta Therapeutics Inc Insider Transactions

No Available Data

What does Bio-Techne Corp do?

Who are the key executives at Bio-Techne Corp?

Christopher S Henney is the director of Bio-Techne Corp. Other key executives at Bio-Techne Corp include PRESIDENT & PROTEIN SCIENCES William Geist , director & Chief Executive Officer Charles R. Kummeth , and SVP - General Counsel Shane Bohnen .

Bio-Techne Corp (TECH) Insider Trades Summary

Over the past 18 months, Christopher S Henney made no insider transaction in Bio-Techne Corp (TECH). Other recent insider transactions involving Bio-Techne Corp (TECH) include a net sale of 80,322 shares made by Charles R. Kummeth , a net sale of 19,339 shares made by Roeland Nusse , and a net sale of 16,000 shares made by Robert V Baumgartner .

In summary, during the past 3 months, insiders sold 0 shares of Bio-Techne Corp (TECH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 119,661 shares of Bio-Techne Corp (TECH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 119,661 shares.

Bio-Techne Corp (TECH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Bio-Techne Corp Insider Transactions

No Available Data

Christopher S Henney Mailing Address

Above is the net worth, insider trading, and ownership report for Christopher S Henney. You might contact Christopher S Henney via mailing address: 10505 Roselle Street, San Diego Ca 92121.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.